deltatrials
Completed PHASE2 INTERVENTIONAL NCT00003646

Gene Therapy in Treating Patients With Stage III or Stage IV Melanoma

Phase II Study of Allovectin-7 as an Immunotherapeutic Agent in Patients With Stages III and IV Melanoma

Sponsor: Vical

Conditions Recurrent Melanoma Stage III Melanoma Stage IV Melanoma
Interventions allovectin-7
Updated 6 times since 2017 Last updated: Jul 5, 2011 Started: Aug 31, 1998 Primary completion: Mar 31, 2002 Completion: May 31, 2002
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Recurrent Melanoma and Stage III Melanoma, this trial is completed. The trial is conducted by Vical and has accumulated 6 data snapshots since 1998. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotCompleted~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 22 months · monthly snapshotCompleted

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

  5. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE2

▶ Show 1 earlier version

  1. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE2

    First recorded

Aug 1998

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Vical
Data source: Vical

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations